Ilya Pharma Receives Approval from Swedish Regulators to Initiate Phase II Clinical Study of ILP100 Gene Therapy to Treat Difficult Wounds Patients with Diabetes
News
Ilya Pharma will present at Bio€quity Europe Digital 17-19 May
Bio€quity hosts Europe’s premier international showcase for financial dealmakers and biopharma executives to meet rising biotechs. Ilya Pharma will share milestones and data from the clinical developments and the emerging pipeline.
Ilya Pharma awarded European patent covering engineered Lactobacillus reuteri strains for use in cutaneous wound therapy
Patent covers treatment of cutaneous human and animal wounds using transformed lactic acid bacteria
Ilya Pharma approved for funding by the European Innovation Council Equity Fund for high-impact innovation
Bloomberg reports: EU will become shareholder in startups for the first time.
Ilya Pharma announces positive results from Phase I trial of lead candidate ILP100 and rapid move to Phase II
Success also de-risks the use of ILP-drug candidates in other medical indications, including the company’s inflammatory bowel disease program.